An Update on the Prevention and Management of Bronchopulmonary Dysplasia

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Critical Care

Background:

• Bronchopulmonary dysplasia (BPD) is a significant cause of morbidity in preterm infants, leading to lasting disabilities.
• Despite advances in neonatal care, the incidence of BPD has remained unchanged over two decades.
• The developing preterm lung is susceptible to injury from mechanical ventilation, oxygen exposure, and infections.

Purpose of the Study:

• To review current therapeutic strategies for preventing and managing BPD in preterm infants.
• To highlight the limitations in evidence supporting existing BPD interventions.
• To emphasize the need for further research to develop effective BPD therapies.

Main Methods:

• Review of current clinical practices and therapeutic approaches for BPD prevention and management.
• Analysis of the evidence base for non-invasive ventilation, surfactant therapy, postnatal corticosteroids, and PDA closure.
• Discussion of the complexities of outpatient BPD management.

Main Results:

• Non-invasive ventilation and minimally invasive surfactant administration aim to reduce lung injury.
• Targeted use of postnatal corticosteroids and PDA closure may individualize care for high-risk infants.
• Most current BPD therapies lack robust evidence of effectiveness.

Conclusions:

• Effective therapies for BPD are lacking, highlighting a critical gap in neonatal care.
• Further research with well-defined outcomes is essential to develop and validate new BPD treatments.
• Improved BPD management strategies are crucial to reduce long-term infant disabilities.